Free tool
FAERS Monitor: Gallium Citrate Ga 67
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018058 or its brand name (Gallium Citrate Ga 67, Gallium Citrate Ga-67). Reports on generic versions are filed under their own applications.
Reports
4
Serious
4
100% of reports
Hospitalization
4
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- erythema2
- inflammation2
- rash pruritic2
- urticaria2
- anaphylactic reaction1
- blood pressure decreased1
- cardiac arrest1
- device related thrombosis1
- electrocardiogram abnormal1
- lung opacity1
- off label use1
- palpable purpura1
- pulmonary oedema1
- treatment noncompliance1
- urine odour abnormal1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| palpable purpura | 1 | 19280.4 | 3516.8 | 4,802 |
| device related thrombosis | 1 | 5343.7 | 977.6 | 1,334 |
| lung opacity | 1 | 1996.0 | 365.4 | 498 |
| urine odour abnormal | 1 | 894.4 | 163.8 | 223 |
| electrocardiogram abnormal | 1 | 670.3 | 122.7 | 167 |
| inflammation | 2 | 203.8 | 76.5 | 227 |
| rash pruritic | 2 | 194.1 | 72.8 | 216 |
| pulmonary oedema | 1 | 117.5 | 21.5 | 28 |
| treatment noncompliance | 1 | 96.1 | 17.6 | 23 |
| anaphylactic reaction | 1 | 95.2 | 17.4 | 23 |
| blood pressure decreased | 1 | 79.1 | 14.5 | 19 |
| cardiac arrest | 1 | 63.7 | 11.7 | 15 |
| urticaria | 2 | 62.8 | 23.6 | 68 |
| erythema | 2 | 51.2 | 19.2 | 55 |
| off label use | 1 | 6.0 | 1.1 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.